Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ONIVYDE safely and effectively. See full prescribing information for ONIVYDE ONIVYDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996
Medication labelWhy this: Advisory · dailymed-prescription
ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14)].
- generic_name
- irinotecan hydrochloride
- product_names
- IRINOTECAN HYDROCHLORIDE
- ndc
- 15054-0043, 15054-0043-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en